Please select an option below to help us tailor your newsletter to best suit your content interests!
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, HER2 positive
Stage 2
Phase 3
Open to Enrollment
N/A
Atezolizumab
PD-L1 inhibitor
Greg Vidal, MD, PhD
Roche/Genentech
HER2 positive early breast cancer
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, ER positive breast cancer
Stage 2
Phase 3
Open to Enrollment
Adjuvant
chemotherapy, ovarian suppression, and endocrine therapy
chemotherapy, ovarian suppression, and endocrine therapy
Greg Vidal, MD, PhD
NRG Oncology
adenocarcinoma
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Triple negative breast cancer, TNBC
Stage 3
Phase 3
Open to Enrollment
Adjuvant
datopotamab deruxtecan (Dato-DXd)
ADC, Trop2 with Topo1 inhibitor payload
Greg Vidal, MD, PhD
AstraZeneca
Triple negative, ER negative, PR negative, HER2 negative
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast Cancer, MBC, IBC
Stage 4
Phase 3
Open to Enrollment
2nd line endocrine
Giredestrant
SERD
Greg Vidal, MD, PhD
Genentech, Inc.
ER positive, HER2 negative
A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination With Phesgo Versus Phesgo After Induction Therapy With Phesgo + Taxane in Patients With Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, IBC
Stage 4
Phase 3
Open to Enrollment
1st
Giredestrant, Phesgo, taxane
SERD, anti-HER2
Saradasri Wellikoff, MD
Roche
HER2 positive, ER positive
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, IBC
Stage 4
Phase 3
Open to Enrollment
1st or 2nd line
Sacituzumab govitecan-hziy
Trop-2 antibody drug conjugate
Greg Vidal, MD, PhD
Gilead Sciences
Triple negative; TNBC
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, IBC
Stage 4
Phase 3
Open to Enrollment
1st line
Sacituzumab govitecan, pembrolizumab
Trop-2 antibody drug conjugate, PD-1 inhibitor
Greg Vidal, MD, PhD
Gilead Sciences
TNBC, PD-L1 positive
A Phase 1b/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Triple Negative Breast Cancer, TNBC
Stage 4
Phase 1
Open to Enrollment
2nd Line
Atezolizumab with Ipatasertib or ladiratuzumab-vidotin or Bevacizumab or Cobimetinib or Capecitabine or Combination Chemo
PD-L1 antibody with either PI3Ki or LIV1A ADC or MEKi or VEGFRi or chemo
Greg Vidal, MD, PhD
Hoffman-La Roche
ER- (negative), PR- (negative), HER2- (negative)
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS- BREAST CANCER)
VIEW TRIAL ON CLINICALTRIALS.GOVbreast cancer
Stage 4
Phase 2
Open to Enrollment
first or second
Giredestrant, Abemaciclib, Ipatasertib, Inavolisib, Ribociclib, Everolimus
multiple
Gregory Vidal, MD
Hoffmann-La Roche
ER+
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes.
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, lung, colon, prostate, bladder, RCC, kidney, skin, melanoma, gastric, pancreatic, HCC, rectal, sarcoma, head and neck, esophagus, biliary tract
Stage 4
Phase 2
Open to Enrollment
Last line
nab-sirolimus
MTOR inhibitor
Dan Vaena, MD
Aadi Bioscience, Inc.
TSC1 or TSC2 alterations
A Phase II Trial of Niraparib and Dostarlimab Combination Therapy in Patients
with Somatic Homologous Recombination Deficient Advanced or Metastatic
Cancer
solid tumors
Stage 4
Phase 2
Open to Enrollment
any
Niraparib and Dostarlimab
PARP inhibitor + IgG4 humanized monoclonal antibody resulting in PDL1/2 inhibition.
Gregory Vidal, MD
West Cancer Center
somatic HRD deficiency
Metastatic, recurrent, or unresectable solid tumor with a pathogenic, or presumed pathogenic, somatic mutation of one of the following homologous recombination deficiency (HRD) gene mutations: BRCA1, BRCA2, ATM, RAD51B, RAD51C, RAD54L, RAD51D, FANC/BRIP1, FANCI, FANCL, FANCN(PALB2), BARD1, CHEK1, CHEK2, CDK12, or PPP2R2A.
Participant must have adequate organ function, defined as follows:
h. Male participant agrees to use a highly effective method of contraception (see Section 5.4 for a list of acceptable birth control methods) starting with the first dose of study treatment through 180 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.
j. If an appropriate archival tumor tissue sample is not available, patient is willing to undergo a pre-treatment tumor biopsy.
Exclusion Criteria:
Patients with the following malignancies will be excluded:
A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Lung, Colon, Prostate, Bladder, Kidney (renal cell), Ovarian, Endometrial (uterine), Cervical, Head and Neck, Melanoma, GBM, Stomach, Liver (HCC), Pancreatic, Gastric, Esophageal, Sarcoma
Stage 4
Phase 1
Open to Enrollment
Any
TAC-001
T-cell receptor agonist antibody drug conjugate
Dan Vaena, MD
Tallac Pharmaceuticals
Histologic documentation
Inclusion Criteria:
Exclusion Criteria:
A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVEsophageal, Gastric, Cervical, clear cell renal cell cancer, RCC, hepatocellular carcinoma, HCC, liver cancer, HNSCC, head and neck cancer, oropharyngeal, larynx, hypopharyngeal, oral cavity, melanoma, urothelial carcinoma, bladder cancer, triple-negative breast cancer, TNBC, non-small cell lung cancer, NSCLC, colon, prostate
Stage 4
Phase 1
Open to Enrollment
>1st line
RO7502175
Anti-CCR8 antibody
Dan Vaena, MD
Genentech, Inc.
Carcinoma
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
VIEW TRIAL ON CLINICALTRIALS.GOVBreast Cancer, Early Breast Cancer, Node-positive breast cancer
Stage 2
Phase 3
Closed to Accrual
Post-neoadjuvant
N/A
N/A
Richard Fine, MD
Alliance for Clinical Trials in Oncology
Node-positive any histology
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer
Stage 2
Phase 3
Closed to Accrual
Adjuvant
Hypofractionated radiotherapy
Radiation
Noam VanderWalde, MD
Alliance for Clinical Trials in Oncology
Invasive ductal, invasive lobular, tubular
Breast, Metastatic Triple Negative Breast Cancer
Stage 4
Phase 1
Closed to Accrual
2nd, 3rd, 4th line
Tremelimumab (and Durvalumab)
anti CTLA-4 antibody (and anti PD-L1 antibody)
Ari VanderWalde, MD, MPH
AstraZeneca
ER negative, PR negative, HER2 negative
A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with Other Anti-cancer Agents in Patients with Metastatic HER2-low Breast Cancer (DESTINY-Breast08)
VIEW TRIAL ON CLINICALTRIALS.GOVBreast Cancer, IDC, ILC
Stage 4
Phase 2
Closed to Accrual
1st, 2nd, or 3rd depending on bucket
trastuzumab deruxtecan (T-DXd). Various arms contain durvalumab, paclitaxel, capivasertib, anastrozole, fulvestrant, and capectabine
HER2 antibody drug conjugate
Greg Vidal, MD, PhD
AstraZeneca
HER2 IHC 1+ or IHC2+ with negative ISH
Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, IBC
Stage 4
Phase 3
Closed to Accrual
1st Line
Trastuzumab Deruxtecan
Anti-body drug conjugate against HER2
Greg Vidal, MD, PhD
AstraZeneca
HER2+ (IHC 3+ or FISH+)
A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, IBC
Stage 3
Phase 3
Closed to Accrual
Neoadjuvant
Trastuzumab Deruxtecan
HER2 antibody-drug conjugate
Greg Vidal, MD, PhD
AstraZeneca
HER2 positive
Histologically documented HER2-positive early breast cancer (EBC) participants, including clinical stage at presentation (based on mammogram or breast MRI assessment): T0-4 (inclusive of inflammatory breast cancer), N1-3, M0 or ≥ T3, N0, M0 as determined by the AJCC staging system, 8th edition
A phase 3, open-label, randomized, parallel, 2-arm, multi-center study of BMN 673 versus physician's choice in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer, who have received no more than 2 prior chemotherapy regimens for metastatic disease (EMBRACA Study)
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Metastatic Breast Cancer
Stage 4
Phase 3
Closed to Accrual
1st line2nd line3rd line
BMN 673
PARP inhibitor
Lee Schwartzberg, MD
BioMarin Pharmaceutical
BRCA 1 mutant or BRCA 2 mutant
Locally advanced or metastatic breast CA
BRCA 1 or 2 germline mutation
Appropriate for single-agent cytotoxic chemotherapy
Prior receipt of anthracycline and/or taxane
No more than 2 prior chemo regimens for metastatic disease
ECOG 0-1
No prior platinum treatment for metastatic disease
No active CNS mets
Adequate organ function
A Phase 1/2 first-in-human study of BMS-986258 alone and in combination with nivolumab in advanced malignant tumors
VIEW TRIAL ON CLINICALTRIALS.GOVRenal cell (kidney), CRC (colon, rectal, colorectal), lung cancer (NSCLC), Head and Neck (SCCHN), Triple Negative Breast (TNBC)
Stage 4
Phase 1
Closed to Accrual
2nd line or greater
BMS 986258
TIM-3 antibody
Dan Vaena, MD
Bristol Myers Squibb
Lung- non-small cell; Breast- Triple Negative; RCC- clear cell; CRC- any; SCCHN- any
An open label phase 2 multi-cohort trial of nivolumab in advanced or metastatic malignancies
VIEW TRIAL ON CLINICALTRIALS.GOVHistiocytosis, Lynch Syndrome Cancer (non-CRC), Medullary Thyroid, Merkel Cell, Abdominal Mesothelioma, Nasopharyngeal, Small cell (non-lung), Penile, Testicular, Thyroid (papillary or follicular), Thyroid (anaplastic-1st line), Uterine Sarcoma, Vulvar Cancer, Small bowel, Adrenocortical, Appendix, endocervical, adenoid-cystic like (HPV+), Cutaneous Adenocarcinoma, Schwannoma
Stage 4
Phase 2
Closed to Accrual
2nd line or later (unless no primary therapy standard)
Nivolumab
PD-1 inhibitor
Lee Schwartzberg, MD
Bristol-Myers Squibb
tumor type specific
Phase I, two-part, multiple, ascending dose study of the anti-HER2 FCAB FS102 in breast, gastric, and other solid tumors
VIEW TRIAL ON CLINICALTRIALS.GOVz- Advanced Solid Tumors, Breast, Gastric, GE junction
Stage 4
Phase 1
Closed to Accrual
After failure of all standard therapies
FS102
Bi-specific anti-HER2 antibody (Fcab)
Daruka Mahadevan, MD, PhD
Bristol-Myers Squibb
HER2 positiveadenocarcinoma
HER2+ adenocarcinoma (by FISH, regardless of IHC)
Unresectable or metastatic last line
ECOG PS 0-1
Limit of prior cumulative doxorubicin dose of 360mg/m2
No CNS disease
No history of prior cancer within last 3 years
No significant cardiac disease
No HIV, HBV, HCV
A multicenter phase 2 study of the glutaminase inhibitor CB-839 in combination with paclitaxel in patients with advanced triple negative breast cancer (TNBC) including patients of African ancestry and non-African ancestry
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Metastatic Breast Cancer, Triple Negative Breast Cancer, TNBC
Stage 4
Phase 2
Closed to Accrual
Cohorts 2 and 4- 1st line; Cohorts 1 and 3- 3rd line or higher
CB-839
Glutaminase Inhibitor
Greg Vidal, MD
Calithera Biosciences, Inc.
Triple negative
Females >18 years old
TNBC defined as ER/PR <1%, HER2 negative
ECOG PS 0-1
Labs within standard limits
No known CNS disease unless adequately treated with XRT or surgery and stable by symptoms for at least 2 months prior
No other malignancy within 3 years (except non-melanoma skin cancer or in situ cancers)
No unstable cardiac disease
No known sensitivity Cremaphor
Cohort 1- 3rd+ line in African ancestry
Must have received prior taxane for metastatic disease but not in most recent treatment
Adjuvant therapy counts as therapy if time to recurrence <12 months
Cohort 2- 1st line in African ancestry- no prior systemic tx for advanced disease
Adjuvant therapy only allowd if time to recurrence >12 mo
Cohort 3- 3rd+ line in non-African ancestry
Similar to Cohort 1
Cohort 4- 1st line in non-African ancestry
Similar to cohort 2
A Phase 1a/1b study of COM701 as monotherapy and in combination with an anti-PD-1 antibody in subjects with advanced solid tumors.
VIEW TRIAL ON CLINICALTRIALS.GOVOvarian, uterine, endometrial, breast, TNBC, lung, colon, CRC, NSCLC, head and neck, SCCHN, gastric, stomach, kidney, renal, RCC, bladder, transitional cell,
Stage 4
Phase 1
Closed to Accrual
Late line
COM-701, PD(L)-1 antibody
PVRIG monoclonal antibody, PD(L)-1 antibody
Dan Vaena, MD
Compugen
A Phase 1/2 Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 in Combination With BMS-986207 (Anti-TIGIT Antibody) and Nivolumab in Subjects With Advanced Solid Tumors.
VIEW TRIAL ON CLINICALTRIALS.GOVEndometrial, Ovarian, Breast, Lung, Colon, Prostate, Gastric, Esophageal, Cervical, Melanoma, Skin, Pancreas, Pancreatic, Sarcoma, Head and Neck (HNPCC), NSCLC, SCLC, Kidney, Bladder, RCC, Prostate
Stage 4
Phase 1
Closed to Accrual
Late line (post standard therapy)
COM-701, BMS-986207, nivolumab
PVRIG antagonist, anti-TIGIT Ab, PD-1 antibody
Dan Vaena, MD
Compugen, Ltd
PVRL2 high (only for basket cohort)
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Pretreated With Prior Standard of Care HER2 Therapies, Including T-DM1
VIEW TRIAL ON CLINICALTRIALS.GOVBreast Cancer, Invasive breast Cancer, BC, IBC
Stage 4
Phase 3
Closed to Accrual
2nd Line or 3rd line (prior T-DM1)
Trastuzumab deruxtecan (DS8201a)
HER-2 targeted ADC
Greg Vidal, MD, PhD
Daiichi Sankyo, Inc.
HER2 positive
z- Advanced Solid Tumors, Breast, Colon, Lung, Prostate, Sarcoma, Bladder, Kidney, Renal, Melanoma, Esophagus, Stomach, Head and Neck, Liver, Pancreatic
Stage 4
Phase 1
Closed to Accrual
Any
LY2835219
CDK 4/6 Inhibitor
Daruka Mahadevan, MD, PhD
Eli Lilly and Company
Any solid tumor
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast Cancer, Hormone Receptor Positive, ER, PR
Stage 2
Phase 3
Closed to Accrual
Post adjuvant chemo, concurrent with endocrine therapy
Abemaciclib
CDK4/6 inhibitor
Lee Schwartzberg, MD
Eli Lilly and Company
ER/PR positive (+) , HER2 negative (-)
Pathologic lymph node involvement and at least one of the following indicating a higher risk of recurrence:
Breast, Early Breast Cancer
Stage 2
Phase 2
Closed to Accrual
N/A
Abemaciclib
CDK4/6 inhibitor
Greg Vidal, MD, PhD
Eli Lilly and Company
ER positive (ER+) or PR positive (PR+) , HER2 negative
Postmenopausal adenocarcinoma of breast
Tumor >1cm in diameter
HR+, HER2-
Neoadjuvant endocrine monotherapy deemed to be suitable therapy
Suitability for baseline core biopsy
No bilateral breast cancer
No inflammatory breast cancer
No metastatic disease
No prior systemic therapy or XRT in same breast as being currently treated
No prior anti-estrogen therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, HER2 positive
Stage 3
Phase 3
Closed to Accrual
Post-adjuvant therapy
Abemaciclib
CDK4/6 inhibitor
Greg Vidal, MD, PhD
Eli Lilly
HER2 positive, ER/PR positive
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, triple negative breast cancer, TNBC
Stage 4
Phase 2
Closed to Accrual
2nd line or greater
Bintrafusp alfa
Bifunctional fusion protein, anti-PD-L1 + TGF-beta trap
Greg Vidal, MD, PhD
EMD Serono Research and Development Institute
ER - (negative), PR - (negative), HER2 - (negative), HMGA2 overexpressing
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVRenal cell carcinoma, hormone receptor positive breast cancer, castration-resistant prostate cancer, urothelial cancer, colorectal cancer (HR+ BC, RCC, CRPC, Bladder, CRC)
Stage 4
Phase 1
Closed to Accrual
Generally at least 1 prior line. Some exceptions
XL092
VEGF/MET kinase inhibitor
Dan Vaena, MD
Exelixis
Breast, Early Breast Cancer
Stage 2
Phase 3
Closed to Accrual
Post-definitive (neo)adjuvant therapy
Neuvax (Nelipepimut-S or E75)
anti-tumor vaccine, active specific immunotherapy
Lee Schwartzberg, MD
Galena BioPharma
HER2 1+ or 2+ (ISH negative) HLA-A2 or HLA-A3 haplotype
Breast, Metastatic Triple Negative Breast Cancer
Stage 4
Phase 2
Closed to Accrual
1st
Ipatasertib
small molecule AKT inihibitor
Greg Vidal, MD, PhD
Genentech, Inc.
ER/PR negative, HER2 negative
A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Trastuzumab Emtansine or With Trastuzumab and Pertuzumab (With and Without Docetaxel) in Patients With HER2-Positive BReast Cancer and Atezolizumab With Doxorubicin and Cyclophosphamide in HER2-Negative Breast Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Metastatic HER2 positive breast cancer
Stage 4
Phase 1
Closed to Accrual
1st line for HER2+, 1st-3rd line for HER2-
Atezolizumab
PD-L1 antibody
Greg Vidal, MD
Hoffmann-La Roche
Any HER2 status, Any ER status
Men or women
Metastatic or locally advanced or recurrent breast cancer
If HER2 negative, no more than two prior chemotherapy lines in metastatic disease and no prior anthracycline
Must have prior treatment with a taxane and trastuzumab in any setting
If treated in 2nd line or later, must have progressive disease since last regimen
If treated in 1st line metastatic, must have progression within 6 months of completing adjuvant therapy
Tumor specimen must be obtained after the most recent breast cancer systemic therapy
ECOG PS 0-2
Measurable disease
LVEF >50% by ECHO or MUGA
Adequate labs
No known CNS disease except for treated asymptomatic supratentorial mets with no need for active steroids
No leptomeningeal disease
A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Trastuzumab Emtansine or With Trastuzumab and Pertuzumab (With and Without Docetaxel) in Patients With HER2-Positive BReast Cancer and Atezolizumab With Doxorubicin and Cyclophosphamide in HER2-Negative Breast Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast Cancer, Breast Neoadjuvant, HER2+
Stage 2
Phase 1
Closed to Accrual
Neoadjuvant
Atezolizumab
PD-L1 antibody
Greg Vidal, MD
Hoffmann-La Roche
HER2 positive
Men or women
Primary tumor size >2cm
Stage at presentation cT2-cT4, cN0-cN3, cM0
HER2 positive disease (ISH positive and/or 3+ by IHC)
HLA-A2 positive (by central laboratory)
ECOG PS 0-2
Adequate lab tests
Baseline LVEF >50% by ECHO or MUGA
No prior systemic therapy for treatment or prevention of breast cancer
No history of DCIS unless >5 years prior to current diagnosis
No Grade 2 or higher peripheral neuropathy
No history of autoimmune disease, need for current immunosuppressants
No HBV/HCV/HIV
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVInvasive breast cancer
Stage 2
Phase 3
Closed to Accrual
N/A
Giredestrant
LHRH antagonist
Greg Vidal, MD, PhD
Hoffmann-La Roche
ER positive, HER2 negative
My Pathway: An open-label Phase IIA study evaluating trastuzumab/pertuzumab, erlotinib, vemurafenib, vismodegib/cobimetinib, alectinib, and atezolizumab in patients who have advanced solid tumors with mutations or gene expression abnormalities predictive of response to one of these agents
VIEW TRIAL ON CLINICALTRIALS.GOVOvarian, breast, CNS (GBM), Liver (HCC), Head and neck (SCCHN), colon, rectum (CRC) bladder, kidney (RCC), prostate, breast, gastric, pancreatic, melanoma (skin)
Stage 4
Phase 2
Closed to Accrual
2nd line or greater
Alectinib
ALK inhibitor
Ari VanderWalde
Genentech, Inc.
ALK gene rearrangements (by NGS or FISH), ALK mutations (NGS), ALK copy number gain (NGS)
My Pathway: An open-label Phase IIA study evaluating trastuzumab/pertuzumab, erlotinib, vemurafenib, vismodegib/cobimetinib, alectinib, and atezolizumab in patients who have advanced solid tumors with mutations or gene expression abnormalities predictive of response to one of these agents
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, Endometrial, Uterine, Ovarian, Cervical, Colon, colorectal, biliary, gastric, esophageal, sarcoma, pancreatic, bladder, prostate
Stage 4
Phase 2
Closed to Accrual
2ndline or later
Atezolizumab
PD-L1 inhibitor
Ari VanderWalde, MD
Genentech
Solid tumor
My Pathway: An open-label Phase IIA study evaluating trastuzumab/pertuzumab, erlotinib, vemurafenib/cobimetinib, vismodegib, alectinib, and atezolizumab in patients who have advanced solid tumors with mutations or gene expression abnormalities predictive of response to one of these agents
VIEW TRIAL ON CLINICALTRIALS.GOVy- Head and neck (SCCHN, oropharynx, larynx, hypopharyx, oral cavity); liver (hepatocellular, HCC); ovarian; colorectal (colon, CRC); esophageal, CNS (brain), breast, lung
Stage 4
Phase 2
Closed to Accrual
Vismodegib
Hedgehog inhibitor
Ari VanderWalde, MD
Genentech, Inc.
Hedgehog activation mutations (PTCH loss of function, SMO gain of function)
Metastatic solid tumor
Loss of function mutation in PTCH or gain of function mutation in SMO
No basal cell CA, medulloblastoma, or SCLC2nd line or greater
ECOG PS 0-2
No prior treatment with any hedgehogdirected therapy
No active or untreated CNS metastastasis_
myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genoic alterations or protein expression pattersn predictive of response: Arm A: Entrectinib in patients with ROS1 fusion-positive tumors
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Colon, Prostate, Small Cell lung, thyroid, head and neck, HNSCC, liver, pancreas, endometrial, cervical, ovarian, skin, melanoma, leukemia, lymphoma, urothelial (bladder), kidney (RCC), myeloma, gastric, small bowel,
Stage 4
Phase 2
Closed to Accrual
Ideally 1st line, but can be later line as well
Entrectinib
TKI against NTRK, ROS, and ALK
Genentech, Inc.
ROS1 fusion. Any cancer type except not NSCLC
myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genoic alterations or protein expression pattersn predictive of response: ArmB: GDC-0077 in patients with PI3K activating mutation-positive tumors
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Lung (NSCLC), Colon, Prostate, Small Cell lung, thyroid, head and neck, HNSCC, liver, pancreas, endometrial, cervical, ovarian, skin, melanoma, leukemia, lymphoma, urothelial (bladder), kidney (RCC), myeloma, gastric, small bowel,
Stage 4
Phase 2
Closed to Accrual
Any line
GDC-0077
PI3K p110 alpha inhibitor
Genentech, Inc.
PIK3CA mutation positive. Any malignancy except NOT CNS tumors
myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response: Arm F: Trastuzumab emtansine plus atezolizumab Arm G: PH FDC SC Arm H: PH FDC SC plus chemotherapy Arm I: trastuzumab emtansine plus tucatinib, in patients with ERBB2 gene amplification- or mutation-positive tumors.
VIEW TRIAL ON CLINICALTRIALS.GOVLung, Colon, Prostate, Small Cell lung, thyroid, head and neck, HNSCC, liver, pancreas, endometrial, cervical, ovarian, skin, melanoma, leukemia, lymphoma, urothelial (bladder), kidney (RCC), myeloma, gastric, small bowel,
Stage 4
Phase 2
Closed to Accrual
Any, but cannot have had prior
TDM-1 with atezolizumab, or PH FDC SC with or without chemotherapy, or TDM-1 with tucatinib
Anti-HER2 agents
Genentech, Inc.
ERBB2 amplification or specific mutation
myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response: Arm J: Trastuzumab emtansine plus atezolizumab in patients with ERBB2 amplification or mutation plus TMB-H/MSI-H/dMMR-positive tumors
VIEW TRIAL ON CLINICALTRIALS.GOVLung, Colon, Prostate, Small Cell lung, thyroid, head and neck, HNSCC, liver, pancreas, endometrial, cervical, ovarian, skin, melanoma, leukemia, lymphoma, urothelial (bladder), kidney (RCC), myeloma, gastric, small bowel,
Stage 4
Phase 2
Closed to Accrual
Any line
TD-M1 + atezolizumab
anti-HER2 agent and anti-PD-L1 agent
Genentech, Inc.
ERBB amplificaiton or mutation AND TMB-h or MSI-h or dMMR
myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genoic alterations or protein expression pattersn predictive of response: ArmC: Alectinib in patients with ALK rearrangement-positive tumors
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Colon, Prostate, Small Cell lung, thyroid, head and neck, HNSCC, liver, pancreas, endometrial, cervical, ovarian, skin, melanoma, leukemia, lymphoma, urothelial (bladder), kidney (RCC), myeloma, gastric, small bowel,
Stage 4
Phase 2
Closed to Accrual
Any line
Alectinib
ALK and RET inhibitor
Genentech, Inc.
ALK rearrangement/fusion in any malignancy except not NSCLC
myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genoic alterations or protein expression pattersn predictive of response: Arm D: Ipatasertib in patients with PTEN Loss/Loss-of-function or AKT activating mutation-positive tumors
VIEW TRIAL ON CLINICALTRIALS.GOVAny: Lung, Breast, Colon, Prostate, Small Cell lung, thyroid, head and neck, HNSCC, liver, pancreas, endometrial, cervical, ovarian, skin, melanoma, leukemia, lymphoma, urothelial (bladder), kidney (RCC), myeloma, gastric, small bowel,
Stage 4
Phase 2
Closed to Accrual
Any line
Ipatasertib
AKT inhibitor
Genentech, Inc.
PTEN loss or loss of function
myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genoic alterations or protein expression pattersn predictive of response: Arm D: Ipatasertib in patients with PTEN Loss/Loss-of-function or AKT activating mutation-positive tumors
VIEW TRIAL ON CLINICALTRIALS.GOVAny: Lung, Breast, Colon, Prostate, Small Cell lung, thyroid, head and neck, HNSCC, liver, pancreas, endometrial, cervical, ovarian, skin, melanoma, leukemia, lymphoma, urothelial (bladder), kidney (RCC), myeloma, gastric, small bowel,
Stage 4
Phase 2
Closed to Accrual
Any line
Ipatasertib
AKT inhibitor
Genentech, Inc.
select AKT mutations
myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genoic alterations or protein expression patterns predictive of response: Atezolizumab plus chemotherapy in patients with TMB-H/MSI-H/dMMR-positive tumors
VIEW TRIAL ON CLINICALTRIALS.GOVAny: Lung, Breast, Colon, Prostate, Small Cell lung, thyroid, head and neck, HNSCC, liver, pancreas, endometrial, cervical, ovarian, skin, melanoma, leukemia, lymphoma, urothelial (bladder), kidney (RCC), myeloma, gastric, small bowel,
Stage 4
Phase 2
Closed to Accrual
Any line but cannot have previously had PD-1
Atezoliumab + chemotherapy (investigators choice- capecitabine, paclitaxel, or docetaxel)
PD-L1 inhibitor + chemotherapy
Genentech, Inc.
TMB high, defined as > or = 10 mutations/megabase
myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genoic alterations or protein expression patterns predictive of response: Atezolizumab plus chemotherapy in patients with TMB-H/MSI-H/dMMR-positive tumors
VIEW TRIAL ON CLINICALTRIALS.GOVAny: Lung, Breast, Colon, Prostate, Small Cell lung, thyroid, head and neck, HNSCC, liver, pancreas, endometrial, cervical, ovarian, skin, melanoma, leukemia, lymphoma, urothelial (bladder), kidney (RCC), myeloma, gastric, small bowel,
Stage 4
Phase 2
Closed to Accrual
Any, but cannot have had prior anti-PD-1 or anti-PD-L1
Atezoliumab + chemotherapy (investigators choice- capecitabine, paclitaxel, or docetaxel)
PD-L1 inhibitor + chemotherapy
Genentech, Inc.
MSI-h or dMMR
Breast Cancer, Early Breast Cancer
Stage 2
Phase 1
Closed to Accrual
N/A
GSK2302024A
WT1-A10 + AS15 Antigen-Specific Cancer Immunotherapeutic
Lee Schwartzberg, MD
GSK (GlaxoSmithKline)
WT1-positive Any ER/PR/HER2 Status
z- melanoma, gastric, colorectal, breast, lung, prostate, pancreas, biliary, head and neck, kidney, bladder, sarcoma, brain
Stage 4
Phase 1
Closed to Accrual
Any, following prior participation on GSK BRF study
Dabrafenib
BRAF inhibitor
Jason Chandler, MD
GlaxoSmithKline
BRAF mutation
Breast, Metastatic Hormone Receptor Positive Breast Cancer
Stage 4
Phase 2
Closed to Accrual
>1 prior line of endocrine therapy<1 line of chemotherapy (not including targeted tx)
GTx-024
Selective Androgen Receptor Modulator (SARM)
Lee Schwartzberg, MD
GTx
AR+ (Androgen Receptor Positive)ER+ (Estrogen Receptor Positive)
Metastatic or recurrent locally advanced BC with disease progression
Post-menopausal
ER positive, AR (Androgen Receptor) positive
HER2- (negative)
At least 1 prior hormonal treatment in metastatic or adjuvant setting
- If receipt in metastatic setting, DoR must have been at least 6 months
-�If receipt in adjuvant setting, DoR must be at least 3 years
No more than 1 course of chemo (not including immuno or targeted therapies) for metastatic disease
No uncontrolled CNS mets (must be stable for 28 days prior to enrollment)
Measurable disease with evidence of progression
ECOG PS 0-1
No HBV or HCV
No hormone replacement therapy
A phase 2 open label, multi-center, multinational study investigating the efficacy and safety of GTx-024 on advanced androgen receptor-positive triple negative breast cancer (AR+ TNBC)
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Metastatic Triple Negative Breast Cancer
Stage 4
Phase 2
Closed to Accrual
2nd line3rd line
GTx-024 (Enobosarm)
Selective androgen receptor modulator
Greg Vidal, MD, PhD
GTx
Breast AdenocarcinomaER/PR negative (-)HER2 negative (-)Androgen Receptor positive (AR+)
FemaleTNBC who have received no more than two prior chemotherapy regimens for TNBC
Confirmation of Androgen Receptor Positive (AR>_10% staining by IHC)
ECOG PS 0-1
No symptomatic or untreated CNS mets
No XRT within 14 days of starting therapy
No other malignancy within last 2 years
No HBV, HCV, HIV
x- HEC for breast cancer, head and neck cancer, hematologic malignancies, leukemia, lymphoma, lung cancer, bladder cancer
N/A
Phase 3
Closed to Accrual
1st Line (Prior targeted or endocrine therapy allowed)
IV Pro-Netupitant/Palonosetron Fixed Dose Combination
Fixed dose combination NK1 antagonist + 5-HT3 antagonist
Lee Schwartzberg, MD
Helsinn Healthcare SA
Any
A Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group Phase 3b Study to Assess the Safety and to Describe the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination (IV NEPA FDC) Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination (Akynzeo®) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Initial and Repeated Cycles of Anthracycline-cyclophosphamide (AC) Chemotherapy in Women With Breast Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Breast Cancer, TNBC, ER+ breast cancer
Stage 2
Phase 3
Closed to Accrual
AC
fosnetupitant/palnosetron (IV) or netupitant/palonosetron (oral)
NK1 receptor antagonist, anti-emetic
Lee Schwartzberg, MD
Helsinn Healthcare SA
Adenocarcinoma
x- breast, head and neck (oropharynx, larynx, hypopharynx,oral cavity), lung, sarcoma
N/A
Phase 3
Closed to Accrual
N/A
APF530 (Granisetron)
Serotonin 5-HT3 receptor antagonist
Lee Schwartzberg, MD
Heron Therapeutics
Any
Breast, Early Breast Cancer
Stage 2
Phase 3
Closed to Accrual
N/A
TDM1 (Kadcyla), pertuzumab (Perjeta)
anti-HER2 antibody, antibody drug conjugate
Lee Schwartzberg, MD
Hoffman-La Roche
HER2 positive
HER2+_ (by IHC or FISH)
Stage II or III (non-metastatic)
If no nodal disease, must be ER/PR negative
>9 weeks sincedefinitive breast surgery
Negative HBV and HCV serology
LVEF>_55%
No prior tx with anti-HER2 therapy, taxanes, or anthracyclines
No known active liver disease
No significant CV disease
A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (HR+ ARM CLOSED)
VIEW TRIAL ON CLINICALTRIALS.GOVBreast Cancer, MBC
Stage 4
Phase 3
Closed to Accrual
1st line chemo
Ipatasertib
PI3 kinase inhibitor
Greg Vidal, MD, PhD
Hoffman-La Roche
Triple negative breast cancer
A Phase III, Double-blind, Placebo-controlled, Randomized Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer.
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, TNBC, Triple negative breast cancer
Stage 4
Phase 3
Closed to Accrual
1st Line
Ipatasertib, atezolizumab, paclitaxel
PI3-kinase inhibitor, PD-L1 inhibitor, taxane
Greg Vidal, MD, PhD
Hoffmann-La Roche
ER negative, PR negative, HER2 negative adenocarcinoma
An open-label, phase I/II, dose-escalation study evaluating the safety and tolerability of GDC-0032 in patients with locally advanced or metastatic solid tumors or non-Hodgkin's lymphoma and in combination with endorcrine therapy in patients with locally advaned or metastatic hormone receptor-positive breast cancer.
VIEW TRIAL ON CLINICALTRIALS.GOVBladder, Head and Neck, Gastric, TNBC, Ovarian
Stage 4
Phase 1
Closed to Accrual
> or = 2nd line
taselisib (GDC-0032)
PI3 kinase delta inhibitor
Ari VanderWalde, MD
Hoffman-La Roche
PIK3CA mutation
A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION (SKYSCRAPER-03)
VIEW TRIAL ON CLINICALTRIALS.GOVLung
Stage 3
Phase 3
Closed to Accrual
Adjuvant
Atezolizumab + Tiragolumab
PDL -1 Inhibitor + Anti-TIGIT antibody
Jason Porter, MD
Hoffmann-La Roche
Non small cell Lung Cancer
Inclusion Criteria:
Exclusion Criteria:
A Phase III, multicenter, randomized placebo-controlled study of atezolizumab (anti-PD-L1 antibody) in combination with nab paclitaxel compared with placebo with nab paclitaxel for patients with previously untreated metastatic triple negative breast cancer.
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Metastatic Triple Negative Breast Cancer
Stage 4
Phase 3
Closed to Accrual
1st Line
Atezolizumab
anti-PD-L1 antibody
Greg Vidal, MD, PhD
Hoffmann-La Roche
ER negative (-), PR negative (-), HER2 negative (-)
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer
Stage 4
Phase 3
Closed to Accrual
1st line (pre-chemo)
GDC-9545
Selective estrogen receptor degrader (SERD)
Greg Vidal, MD, PhD
Hoffmann-LaRoche
ER+ (positive), HER2 - (negative)
Cryoablation of low risk breast cancer less than 1.5 cm: An evaluation of local recurrence (Ice-3 trial)
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, early
Stage 1
Phase 2
Closed to Accrual
N/A
Ice-Sense3TM
Cryoablative device
Richard Fine, MD, FACS
IceCure Medical
Invasive ductal carcinomaER positivePR positiveHER2 negativeKi-67 <14%
Phase III Study of Sacituzumab Govitecan (IMMU-132) in Refractory/Relapsed Triple-Negative Breast Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast Cancer, Triple negative, TNBC
Stage 4
Phase 3
Closed to Accrual
3rd Line or later
Sacitzumab govitecan
Antibody-drug conjugate (ADC) of TROP-2 antibody
Lee Schwartzberg
Immunomedics, Inc
ER negative, PR negative, HER2 negative
Phase 3 Study of Sacituzumab Govitecan vs Physician's Choice in Subjects With Hormonal Receptor-Positive Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer Who Have Failed at Least 2 Prior Chemotherapy Regimens
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, ER positive breast cancer, MBC, PR positive breast cancer, HER2 negative breast cancer
Stage 4
Phase 3
Closed to Accrual
3rd Line or greater
Sacituzumab govitecan
ADC for Trop-2
Lee Schwartzberg, MD
Immunomedics, Inc
ER/PR +, HER2-
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
VIEW TRIAL ON CLINICALTRIALS.GOVSolid Tumors: Breast, Lung (NSCLC), Colon, Prostate, Bladder, Kidney, Esophagus, Stomach (Gastric), Liver (HCC), Cervical, Endometrial, Ovarian, Skin, Head and Neck (SCCHN), Bladder, Kidney (renal cell), Pancreatic, Rectal, Brain (GBM, glioblastoma)
Stage 4
Phase 2
Closed to Accrual
Following all effecive therapy (late line)
Pemigatinib
FGFR inhibitor
Dan Vaena, MD
Incyte Corporation
FGFR 1,2,3 mutated or FGFR 1,2,3 fusion/translocation
Breast, Metastatic Breast Cancer
Stage 4
Phase 2
Closed to Accrual
3rd or higher systemic therapy (Endocrine therapy counts as systemic therapy)
Enzalutamide
AR antagonist
Lee Schwartzberg, MD
Medivation Inc./ Astellas Pharmaceuticals
AR positive (+) ER/PR positive (+) HER2 negative (-)
Breast, Metastatic Breast Cancer
Stage 4
Phase 2
Closed to Accrual
1st or 2nd
Enzalutamide
Androgen receptor antagonist
Lee Schwartzberg, MD
Medivation Inc, Astellas Pharmaceuticals
ER/PR positive (+)HER2 negative (-)
Breast, Metastatic triple negative breast cancer, TNBC
Stage 4
Phase 3
Closed to Accrual
2nd or 3rd line
Pembrolizumab
PD-1 inhibitor
Greg Vidal, MD, PhD
Merck Sharp & Dohme Corp.
ER negative (ER -), PR negative (PR -), HER2 negative (HER2 -)
A phase III, randomized, double-blind study to evaluate pembrolizumab plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab vs placebo as adjuvant therapy for triple negative breast cancer
VIEW TRIAL ON CLINICALTRIALS.GOVTriple Negative Breast Cancer
Stage 2
Phase 3
Closed to Accrual
Neoadjuvant
Pembrolizumab
PD-1 inhibitor
Greg Vidal, MD, PhD
Merck Sharp & Dohme Corp.
ER negative, PR negative, HER2 negative
A Phase 1 Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Triple Negative Breast Cancer, TNBC
Stage 4
Phase 1
Closed to Accrual
2nd or 3rd line
MK-5890
CD27 agonist
Dan Vaena, MD
Merck Sharp & Dohme Corp
ER negative, PR negative, HER2 negative
A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Triple Negative Breast Cancer
Stage 4
Phase 2
Closed to Accrual
2nd line or 3rd line
Lenvatinib and Pembrolizumab
VEGF-R/FGFR inhibitor and PD-1 inhibitor
Manjari Pandey, MD
Merck Sharp & Dohme Corp
TNBC
ON TARGET: A Phase 3 multicenter, randomized, double-blind placebo-controlled trial evaluating crofelemer for the prophylaxis of diarrhea in adult patients with solid tumors
receiving targeted-cancer therapies with or without standard chemotherapy regimens
Breast, Lung, Bladder, Gastric, Esophageal, Kidney, Renal, RCC, NSCLC, Melanoma, thyroid, sarcoma, liver, HCC, GIST, PNET,
Stage 4
Phase 3
Closed to Accrual
Any
Crofelemer
Botanical oligomeric proanthocyanidin
Lee Schwartzberg, MD
Napo Pharmaceuticals
Any
A Phase 3 open-label, randomized, multicenter study of NKTR-102 versus treatment of physician’s choice (TPC) in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane, and capecitabine (ATTAIN)
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Metastatic Breast Cancer, stable brain metastases, MBC
Stage 4
Phase 3
Closed to Accrual
2nd line or greater
NEKTR 102 (etirinotecan pegol)
pegylated pro-drug
Lee Schwartzberg, MD
Nektar Therapeutics
Adenocarcinoma (any ER/PR/HER2 status)
Any gender
Single-agent cytotoxic chemotherapy indicated
Can be measurable or non-measurable disease
Must have a history of brain metastases that are non-progressing
In TNBC, must have at least 1 prior lines of metastatic cytotoxic therapy
In non-TNBC, prior therapy as indicated is required
Have received prior therapy with anthracycline, taxane, and capecitabine in any setting (neo-adj, adj, or metastatic)
Most recent anti-cancer therapy within 6 months of randomization
ECOG PS 0-1
No prior SCT
No prior camptothecin-derived agent
No leptomeningeal disease
No HBV/HCV/HIV
No cirrhosis
No other malignancy within 5 years
No need for O2 supplementation
y- breast, lung, melanoma, prostate, colorectal, head and neck, gastric, renal, leukemia, lymphoma, sarcoma, ovarian
Stage 4
Phase 2
Closed to Accrual
>/= 2nd line
BGJ398
FGFR inhibitor
Daruka Mahadevan, MD, PhD
Novartis Pharmaceuticals
FGFR genetic alteration
Must have FGFR gene alteration as measured in CLIA-certified lab
None of the following malignancies:
Bladder cancer (urothelial)
Cholangiocarcinoma
Endometrial cancer
Glioblastoma multiforme (GBM)
Received at least 1 prior line of therapy
No standard therapy expected to result in durable remission
ECOG PS 0-1
No CNS disease
No acute/chronic pancreatitis
No impared cardiac function
No corneal or retinal disorder
No other cancer within 3 years
_
Breast, Metastatic Hormone Receptor Positive Breast Cancer
Stage 4
Phase 3
Closed to Accrual
1st line chemo (after failure of mTOR inhibitor)2nd line chemo�(after failure of mTORi AND one line of chemo)
BKM120
Pan-class 1 PI3K inhibitor
Jason Chandler, MD
Novartis Pharmaceuticals
ER/PR positive (+)HER2 negative (-)
Postmenopausal women
Locally advanced or metastatic breast cancer
HER2-, ER/PR+
Most recent progression must be on combination mTORi and AI
No more than one prior metastatic chemo regimen
No chronic steroid treatment
No active cardiac disease
�
y- Advanced Cancer; Head and Neck (SCCHN), Non-Hodgkin Lymphoma (NHL), Ovarian, Bladder (Urothelial), Cervical, Liposarcoma, Adenoid Cystic
Stage 4
Phase 2
Closed to Accrual
>/=2nd line
BKM120
PI3K inihibitor
Lee Schwartzberg, MD
Novartis Pharmaceuticals
PI3K activation (PI3K mutation, PTEN mutation, loss of PTEN, PI3K amplification, or loss-of-function mutation of PI3KR1)
y- breast, colon, prostate, colorectal, sarcoma, melanoma, bladder, renal, head and neck, leukemia, lymphoma, gastric, esophageal, ROS1 positive lung
Stage 4
Phase 2
Closed to Accrual
>/= 2nd line
Ceritinib
ALK inhibitor
Daruka Mahadevan, MD, PhD
Novartis Pharmaceuticals
ALK or ROS1 mutation, translocation, rearrangement, or amplification
ALK or ROS1 mutation, trnaslocation, rearrangement, or amplification by CLIA-certified laboratory (IHC or FISH allowed)
May not have ALK+ lung cancer (butROS1 positive lung CA allowed)
Relapsed or progressive disease
ECOG PS 0-1
2nd line or higher
No standard therapy withdurable remission expected
No CNS disease
Breast Cancer, Early Breast Cancer
Stage 1
Phase 2
Closed to Accrual
N/A
LEE011
CDK 4/6 Inhibitor
Lee Schwartzberg, MD
Novartis
ER+ or PR+ (positive) HER2 - (negative)Grade 2 or 3 invasive disease
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negartive Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, Invasive breast cancer, BC
Stage 2
Phase 3
Closed to Accrual
Aduvant
Ribociclib
CDK4/6 inhibitor
Lee Schwartzberg, MD
Novartis Pharmaceuticals
ER or PR positive (HR+), adenocarcinoma
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast Cancer, Hormone Receptor Positive Breast Cancer
Stage 3
Phase 3
Closed to Accrual
Following (neo)adjuvant chemo
ribociclib
CDK4/6 inhibitor
Lee Schwartzberg, MD
Novartis Pharmaceuticals
ER/PR +, HER2-
y- Colorectal, Ovarian, Gastric, Kidney, Leukemia, Lymphoma, Head and Neck, Breast Cancer, Esophagus, Liver, Bladder
Stage 4
Phase 2
Closed to Accrual
No further standard therapies
LEE011
CDK4/6 Inhibitor
Lee Schwartzberg, MD
Novartis Pharmaceuticals
CDK4/6, cyclin D1/3, or p16 aberrations
y- Advanced Cancer; non-squamous NSCLC (non-small cell lung), Melanoma, Ovarian, Thyroid, Multiple Myeloma, GIST (gastrointestinal stromal tumor), AML (acute myeloid leukemia)
Stage 4
Phase 2
Closed to Accrual
>/=2nd line
Dovitinib (TKI258)
Angiogenesis inhibitor
Daruka Mahadevan, MD, PhD
Novartis Pharmaceuticals
Mutations or transolocations in: FGFR PDGFR VEGF cKIT FLT3 CSFR1 Trk RET
A randomized phase III clinical trial evaluating post-mastectomy chestwall and regional nodal XRT and post-lumpectomy regional nodal XRT in patients with positive axillary nodes before neoadjuvant chemotherapy who convert to pathologically negative axillary nodes after neoadjuvant chemotherapy
VIEW TRIAL ON CLINICALTRIALS.GOVBreast Cancer, Early Breast Cancer, Node-positive breast cancer
Stage 2
Phase 3
Closed to Accrual
Post-neoadjuvant
regional nodal irradiation
N/A
Noam VanderWalde, MD
NSABP Foundation
Node positive prior to surgery, pathologically node negative at surgery
Patients must have pathologic confirmation of axillary nodal involvement at presentation (before neoadjuvant therapy) based on a positive FNA (demonstrating malignant cells) or positive core needle biopsy (demonstrating invasive adenocarcinoma). Patients may not have had documentation of axillary nodal positivity by sentinel node biopsy (before neoadjuvant therapy).
Patient must have clinically T1-3, N1 breast cancer at the time of diagnosis (before neoadjuvant chemotherapy)
Hormone receptor status must be performed on the primary breast tumor before neoadjuvant chemotherapy.
HER2 status must be performed on the primary breast tumor before neoadjuvant chemotherapy. Patients who have a primary tumor that is either HER2-positive or HER2-negative are eligible)
Patients must have completed a minimum of 8 weeks of standard neoadjuvant chemoterahyp consisting of an anthracycline and/or taxane-based regimen
For patients who receive adjuvant chemotherapy after surgery a maximum of 12 weeks of intended chemotherapy may be administered but must be completed before randomization
Patients with HER2-positive tumors must have received neoadjuvant anti-HER2 therapy (with all or with a portion of the neoadjuvant chemotherapy regimen), unless medically contraindicated.
At the time of definitive surgery, all removed axillary nodes must be histologically free of cancer
ECOG PS 0-1
Randomized, Phase 3 Study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2 Negative, HR Positive, Locally advanced or metastatic breast cancer previously treated with a taxane
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Breast Cancer
Stage 4
Phase 3
Closed to Accrual
1st or 2nd Line Chemotherapy after receipt of adjuvant/neoadjuvant taxane. Any number of prior endocrine tx allowed.
Tesetaxel
Orally administered taxane
Lee Schwartzberg, MD
Odonate Therapeutics
Hormone Receptor Positive, ER Positive, PR positive, HER2 Negative, HER2-
A Phase I/II, Open-Label, Dose Escalation and Cohort Expansion Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
VIEW TRIAL ON CLINICALTRIALS.GOVColon, Ovarian, Gastric, Pancreatic, Endometrial, lung, prostate, breast
Stage 4
Phase 1
Closed to Accrual
Late line
OBI-888
Anti-globo-H antibody
OBI Pharma
Globo-H overexpression
A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-999 in Patients With Advanced Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVPancreatic, Esophageal, Gastric, Colorectal, Breast, Lung, Prostate, Melanoma, Head and Neck, Sarcoma, Bladder, Renal Cell, Ovarian, Endometrial, Cervical
Stage 4
Phase 1
Closed to Accrual
Late line
OBI-999
Globo H targeting agent
Dan Vaena, MD
OBI Pharma
Any solid tumor
Multinational, Multicenter, Phase 2 Study of Tesetaxel Plus a Reduced Dose of Capecitabine in Patients With HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, invasive breast cancer, BC, hormone receptor positive BC
Stage 4
Phase 2
Closed to Accrual
1st line chemo (most likely)
tesetaxel
oral taxane
Lee Schwartzberg, MD
Odonate Therapeutics, Inc.
ER/PR positive, HER2 negative
A Multicenter, Phase 2 Study of Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Elderly Patients With HER2 Negative MBC
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, triple-negative breast cancer, TNBC
Stage 4
Phase 2
Closed to Accrual
1st Line
Tesetaxel, nivolumab, pembrolizumab, atezolizumab
oral taxane, PD-1 or PD-L1 inhibitors
Lee Schwartzberg, MD
Odonate Therapeutics, Inc.
ER negative, PR negative, HER2 negative
A Multicenter, Phase 2 Study of Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Elderly Patients With HER2 Negative MBC
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Metastatic Breast Cancer, MBC,
Stage 4
Phase 2
Closed to Accrual
1st Line Chemo
Tesetaxel
Oral taxane
Lee Schwartzberg, MD
Odonate Therapeutics, Inc.
HER2 negative (Any ER or PR status)
A prospective, multi-center, randomized, double-arm trial to determine the impact of the SELENE system on positive margin rates in breast conservation surgery
VIEW TRIAL ON CLINICALTRIALS.GOVBreast
Stage 2
Phase 2
Closed to Accrual
First line
Selene
Optical Coherence Tomography (OCT)
Richard Fine, MD
PERIMETER
Inclusion Criteria:
Exclusion Criteria:
Breast: Metastatic Breast
Stage 4
Phase 4
Closed to Accrual
Any
Palbociclib
CDK4/6 inhibitor
Lee Schwartzberg, MD
Pfizer
ER or PR positive HER2 negative
z- Advanced Solid Tumors; Breast Cancer (HER2+ only) or lung cancer (squamous cell NCLC only)
Stage 4
Phase 1
Closed to Accrual
>2nd line for NSCLC, >3rd line for breast
Ibrutinib and MEDI4736
Bruton's Tyrosine Kinase (BTK) Inihibitor (Ibrutinib), PD-L1 inhibitor (MEDI4736)
Jason Chandler, MD
Pharmacyclics
TNBC or HER2+�breast cancerAdenocarcinoa or squamous carcinoma of lung
Either NSCLC (squamous only), Breast Cancer (HER2+ only)
Relapsed/refractory disease
One or more measurable disease lesions
ECOG PS 0-1Coags within 1.5x ULN
Creatinine within 2x ULN
No CNS involvement
No prior tx with BTK inhibitors (eg.ibrutinib), or immune tx (CTLA-4, PD-1, PD-L1).
No systemic steroids >10mg daily prednisone within last 14 days except as given as premed
No current or prior autoimmune disorders within 3 years
No other malignancies within 5 years
No known HBV/HCV/HIV
A study of neratinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2+ metastatic breast cancer who have received two or more prior HER2-directed regimens in the metastatic setting (NALA).
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Metastatic HER2 positive Breast Cancer
Stage 4
Phase 3
Closed to Accrual
>2nd line
Neratinib
pan-HER TKI
Greg Vidal, MD, PhD
Puma Biotechnology
HER2+
Metastatic breast cancer
HER2 overexpression or gene amplified tumor (IHC3+ or IHC2+ with positive FISH)
Prior treatment with at least 2 HER2-directed regimens for metastatic breast cancer
Measurable disease per RECIST 1.1
ECOG PS 0-1
No prior therapy with capecitabine, neratinib, lapatinib, or other HER2 directed TKI.
No active (symptomatic CNS mets)
No significant chronic GI disorder with diarrhea as a major symptom
An open-label, multicenter, multinational, phase 2 study exploring the efficacy and safety of neratinib therapy in patients with solid tumors with activating HER2, HER3 or EGFR mutations or with EGFR gene amplification
VIEW TRIAL ON CLINICALTRIALS.GOVBladder, Breast, Brain (GBM), Head and Neck, Prostate, Kidney (Renal Cell), Melanoma, Ovarian, Endometrial (Uterine), Cervical, Gastric, Pancreatic, Hepatocellular (HCC), Esophageal, lymphoma, sarcoma
Stage 4
Phase 2
Closed to Accrual
Any (provided no curative therapy available)
Neratinib
pan-HER TKI
Lee Schwartzberg, MD
Puma Biotechnologies
HER2 (ERBB2) mutation or HER4 (ERBB4 mutation), or EGFR ex. 18 mutated lung cancer
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, invasive breast cancer, IBC
Stage 4
Phase 3
Closed to Accrual
2nd Line (post CDK4/6 inh)
Elacestrant
Selective Estrogen Receptor Degrader (SERD)
Greg Vidal, MD, PhD
Radius Pharmaceuticals, Inc.
adenocarcinoma, ER/PR +, HER2-
An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2− Breast Cancer With an ESR1 Mutation
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, invasive breast cancer, BC, hormone receptor positive BC
Stage 4
Phase 2
Closed to Accrual
2nd Line or later endocrine tx
Lasofoxifene
SERM
Lee Schwartzberg, MD
Sermonix Pharmaceuticals LLC
ER positive, HER2 negative
Randomized trial of SPI-2012 versus pegfilgrastim in the management of chemotherapy induced neutropenia in breast cancer patients receiving docetaxel and cyclophosphamide
VIEW TRIAL ON CLINICALTRIALS.GOVx- Breast Cancer, Early Breast Cancer, IDC, ILC
Stage 2
Phase 3
Closed to Accrual
N/A
SPI-2012
Long-acting myeloid growth factor
Lee Schwartzberg, MD
Spectrum Pharmaceuticals, Inc
Any
Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk hormone receptor-positive and HER2/Neu negative breast cancer. E3 Breast cancer study- evaluating everolimus with endocrine therapy
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, early breast cancer
Stage 2
Phase 3
Closed to Accrual
N/A
everolimus
MTOR inhibitor
Lee Schwartzberg, MD
Southwest Oncology Group
High risk early breast cancer as defined as follows:
HER2 negative, ER/PR positive
Completed standard neoadjuvant or adjuvant taxane or anthracycline therapy
No prior receipt of MTOR inhibitors
ECOG PS 0-2
Fasting cholesterol <300, TG <2.5x ULN
HIV positive allowed if controlled CD4 count and NOT on ART
Phase 1/2 clinical study of niraparib in combination with pembrolizumab in patients with advanced or metastatic triple-negative breast cancer and in patients with recurrent ovarian cancer
VIEW TRIAL ON CLINICALTRIALS.GOVOvarian cancer, fallopian tube cancer, primary peritoneal cancer
Stage 4
Phase 1
Closed to Accrual
2nd line to 5th line
Niraparib, Pembrolizumab
PARP inhibitor, PD-1 inhibitor
Lee Schwartzberg, MD
Tesaro, Inc
High-grade serous
Phase 1/2 clinical study of niraparib in combination with pembrolizumab in patients with advanced or metastatic triple-negative breast cancer and in patients with recurrent ovarian cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Metastatic triple-negative breast cancer, TNBC
Stage 4
Phase 1
Closed to Accrual
2nd line to 4th line
Niraparib, Pembrolizumab
PARP inhibitor, PD-1 inhibitor
Lee Schwartzberg, MD
Tesaro, Inc
ER- (negative), PR- (negative), HER2- (negative) adenocarcinoma
Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies
VIEW TRIAL ON CLINICALTRIALS.GOVLung, Breast, Colon, Pancreas, Bladder, Kidney, Prostate, Melanoma, Lymphoma, Gastric, Head and Neck (SCCHN)
Stage 4
Phase 1
Closed to Accrual
Any line as long as appropriate to give study acceptable chemo in combination
TTX-030
anti CD-39
Dan Vaena, MD
Trishula Therapeutics, Inc.
Any malignancy
Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast Cancer, Metastatic Breast Cancer, MBC
Stage 4
Phase 2
Closed to Accrual
Any (pre-fulvestrant)
Enzalutamide
Androgen receptor inhibitor
Greg Vidal, MD, PhD
University of Colorado, Department of Defense
ER+, HER2-
Randomized phase II trial of preoperative fulvestrant with or without enzalutamide in ER+/HER2- breast cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, Hormone receptor positive breast cancer, locally advanced BC
Stage 2
Phase 2
Closed to Accrual
N/A
Enzalutamide and fulvestrant
Androgen receptor inhibitor
Greg Vidal, MD, PhD
University of Colorado, Department of Defense
ER positive, HER2 negative
Phase II Trial Evaluating the Efficacy and Safety of Neoadjuvant Neratinib and Chemotherapy in Early Stage Triple-Negative Breast Cancer Patients Who Exhibit Enhanced HER2 Signaling by Live Cell HER2 Signaling Transduction Analysis (FACT-2)
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Triple Negative Breast Cancer
Stage 2
Phase 2
Closed to Accrual
Neoadjuvant
Neratinib
HER2 targeted small molecule
Greg Vidal, MD, PhD
West Cancer Center, Puma Biotechnology, Celcuity
ER negative, PR negative, HER2 negative
Breast, Metastatic Breast Cancer
Stage 4
Phase 2
Closed to Accrual
1st line2nd line3rd line
Veliparib
PARP inhibitor
Lee Schwartzberg, MD
AbbVie (Abbott)
BRCA germline mutation
Unresectable recurrent or metastatic disease
BRCA1 or BRCA2 germline mutation
ECOG 0-2
If HER2 positive, must have either progressed on HER2 tx or ineligible to receive HER2 tx
No more than 2 prior lines of cytotoxicchemotherapy
No prior taxane therapy in metastatic setting
No brain mets or history of brain mets
Not pregnant or breastfeeding_
z- Advanced Solid tumors, Breast cancer, TNBC, ovarian
Stage 4
Phase 1
Closed to Accrual
2nd line or later
AMG 900
Aurora kinase inhibitor
Daruka Mahadevan, MD, PhD
Amgen
TNBC or ovarian CA
Breast, Metastatic HER2 negative breast cancer,
Stage 4
Phase 1
Closed to Accrual
1st, 2nd, or 3rd
olaparib
PARP inhibitor
Greg Vidal, MD, PhD
AstraZeneca
HER2 neg. HR+ or HR-